JTEC Corporation

3446.T
Medical Instruments & Supplies
2026/09/28 18:47 Updated
Market Cap: $59.3M (¥9.3B)
Stock Price: $10.04 (¥1,579)
Exchange Rate: 1 USD = ¥157.23

Notice of Revision to Full-Year Consolidated Earnings Forecast

Full-year consolidated earnings forecast for the fiscal year ending June 2026 revised downward. Net sales reduced from previous forecast of 2,655 million to 1,955 million (down 26.3%), operating income from 278 million to 73 million (down 73.6%), ordinary income from 274 million to 85 million (down 69.0%), net income attributable to owners of the parent from 172 million to 59 million (down 65.5%). The factors include shortfalls in sales plans and delays in next-generation products across Optical, Life Science & Instrumentation, and Other Electronics segments, leading to difficult-to-attain targets.

Importance:
Page Updated: July 10, 2026
IR Disclosure Date: July 10, 2026

Key Figures

  • Sales: 1,955 million (from previous forecast 2,655 million, down 26.3%)
  • Operating income: 73 million (from previous forecast 278 million, down 73.6%)
  • Net income attributable to owners of the parent: 59 million (from previous forecast 172 million, down 65.5%)

AI要約

Key points of performance

In today's board meeting, we revised downward the full-year consolidated earnings forecast for the fiscal year ending June 2026. The primary factors are material issues and design changes causing delays in the Optical business, delays in next-generation processing and grinding equipment in Life Science & Instrumentation, and underachievement in sales plans in Electronic Science. Net sales are expected to decline 26.3%, with all profit measures significantly below the previous forecast.

Impact by segment and outlook

The Optical business faces delays due to material processing defects and design changes. Life Science & Instrumentation suffers from delayed sales of the next-generation processing and polishing equipment. Other Electronics also underperforms against plans. Although selling, general and administrative expenses have been cut by about 15.3%, overall profitability remains challenged. For a recovery, progress on individual projects and improved product sales planning are essential.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

JTEC Corporation

Company overview · Stock price · Financial data · All IR

View company page →